A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications.

@article{Holman2005ARD,
  title={A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications.},
  author={Andrew Holman and Robin R Myers},
  journal={Arthritis and rheumatism},
  year={2005},
  volume={52 8},
  pages={2495-505}
}
OBJECTIVE To assess the efficacy and safety of pramipexole, a dopamine 3 receptor agonist, in patients with fibromyalgia. METHODS In this 14-week, single-center, double-blind, placebo-controlled, parallel-group, escalating-dose trial, 60 patients with fibromyalgia were randomized 2:1 (pramipexole:placebo) to receive 4.5 mg of pramipexole or placebo orally every evening. The primary outcome was improvement in the pain score (10-cm visual analog scale [VAS]) at 14 weeks. Secondary outcome… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 34 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 87 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 35 references

Preliminary efficacy of the dopamine agonist, pramipexole for fibromyalgia: the first, open label, multicenter experience

  • AJ Holman, RA Neiman, RE. Ettlinger
  • J Musculoskel Pain 2004;12:69–74
  • 2004
Highly Influential
4 Excerpts

Fibromyalgia syndrome: a central role for the hippocampus: a theoretical construct

  • PB Wood
  • J Musculoskeletal Pain
  • 2004
1 Excerpt

Treatment of fibromyalgia with the dopamine agonist ropinirole: a 14-week double-blind pilot randomized controlled trial (RCT) with 14-week blinded extension [abstract

  • AJ Holman
  • Arthritis Rheum 2004;50 Suppl 9;S698
  • 2004
1 Excerpt

Similar Papers

Loading similar papers…